Red Tree and RA Capital, two investment firms, led a $108m Series B round in Bicara Therapeutics, a clinical-stage biotechnology company, with participation from F-Prime Capital, Eight Roads Ventures, Invus, Piper Heartland Healthcare Capital, Premji Invest, Omega Funds, Bioqube Ventures, Acorn Bioventures and Janus Henderson Investors. “RA Capital Management is excited to co-lead this round to support Bicara’s efforts to develop a differentiated approach to treating cancer. Bicara has reported compelling clinical data demonstrating BCA101’s potential as a more efficacious treatment option for patients with several types of solid tumors and we are committed to supporting this exceptional team as they advance this program toward key data milestones," Jake Simson, RA Capital Management Partner.